You just read:

CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts

News provided by

Cell Therapeutics, Inc.

Mar 03, 2014, 01:30 ET